Business Wire

Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO

LONDON--(BUSINESS WIRE)--Virion Biotherapeutics announced today the appointments of Vanessa King, PhD, as President & Chief Executive Officer and Isabel Najera, PhD, as Chief Scientific Officer.
Nasdaq

Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic ...

PHILADELPHIA, Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean ...
FierceBiotech

Virion Biotherapeutics fills out executive ranks with CEO, CSO

Virion Biotherapeutics announced Monday that Vanessa King and Isabel Najera have signed on as CEO and chief scientific officer, respectively. King has held a number of business development and ...
Nasdaq

Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B ...

Providence, RI, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research ...
JSTOR Daily

The Virion-Packaged Endoribonuclease of Herpes Simplex Virus 1 Cleaves mRNA in Polyribosomes

This is a preview. Log in through your library . Abstract The virion host shutoff protein product of the U L 41 gene of herpes simplex virus 1 is an endoribonuclease that selectively degrades mRNAs ...